COVID-19 presentations and outcome in patients with epilepsy.
COVID
coronavirus
epilepsy
mortality
seizure
Journal
Acta neurologica Scandinavica
ISSN: 1600-0404
Titre abrégé: Acta Neurol Scand
Pays: Denmark
ID NLM: 0370336
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
revised:
24
01
2021
received:
05
01
2021
accepted:
31
01
2021
pubmed:
17
2
2021
medline:
11
5
2021
entrez:
16
2
2021
Statut:
ppublish
Résumé
To determine whether patients with epilepsy (PWE) are particularly over-represented in a very large cohort of patients with COVID-19. We also investigated whether COVID-19 is associated with a different clinical picture or a more severe course of illness in PWE (compared with others). All consecutive patients who referred to and admitted at healthcare facilities anywhere in Fars province (located in the south of Iran with a population of 4,851,000 people) from February 19, 2020 until November 20, 2020 were included. A total of 37,968 patients were studied. Eighty-two patients (0.2%) had pre-existing epilepsy. Seizures were significantly more frequent among PWE as a presenting manifestation of COVID-19 compared with that in people without epilepsy (Odds Ratio = 27; p = 0.0001). Furthermore, PWE less often reported cough (significantly) and more often had gastrointestinal symptoms (vomiting and anorexia; as trends) compared with those in people without epilepsy. Patients with epilepsy were not differently likely to be intubated or admitted at ICUs. Case fatality rates were not different between the two groups [9.8% in PWE and 8.5% in people without epilepsy; p = 0.690]. Patients with epilepsy are not susceptible to contracting COVID-19 more than other individuals. Furthermore, COVID-19 in PWE is not associated with a more severe illness or a poorer prognosis. However, PWE and COVID-19 may present somewhat differently than others with such an illness. Why PWE less often present with cough and more often present with gastrointestinal symptoms is not clear yet and should be investigated and clarified in the future studies.
Identifiants
pubmed: 33590880
doi: 10.1111/ane.13404
pmc: PMC8014655
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
624-628Subventions
Organisme : Shiraz University of Medical Sciences
ID : 12345
Informations de copyright
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Ann Pharmacother. 2013 May;47(5):744-54
pubmed: 23606552
Neurology. 2020 Sep 8;95(10):e1417-e1425
pubmed: 32554773
Acta Neurol Scand. 2020 Oct;142(4):392-395
pubmed: 32632917
PLoS One. 2020 Oct 23;15(10):e0241265
pubmed: 33095835
Neurology. 2017 Jan 17;88(3):296-303
pubmed: 27986877
Front Med (Lausanne). 2020 Oct 30;7:588711
pubmed: 33195352
J Autoimmun. 2020 May;109:102433
pubmed: 32113704
Clin Neurol Neurosurg. 2021 Jan;200:106349
pubmed: 33172719
Epileptic Disord. 2020 Aug 1;22(4):439-442
pubmed: 32759092
Front Neurol. 2020 Jul 03;11:737
pubmed: 32719655
Neurol Sci. 2021 Feb;42(2):415-431
pubmed: 33237493
Acta Neurol Scand. 2021 May;143(5):475-480
pubmed: 33222160
Transplantation. 2021 Jan 1;105(1):61-66
pubmed: 33208691
Seizure. 2020 Jul;79:49-52
pubmed: 32416567